Anti-atherosclerotic use of 17 alpha-dihydroequilin
US5482935A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 1, 1993 |
| Grant date | Jan 9, 1996 |
| Priority date | — |
| Expiry date | Dec 1, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for the treatment of atherosclerosis by administering to a patient in need of anti-atherosclerotic treatment, an effective amount of 17 alpha-dihydroequilin, a C.sub.2 -C.sub.6 alkanoyloxy ester thereof or a pharmaceutically acceptable salt of it's sulfate or phosphate ester, in the absence of naturally occurring estrogenic sreroids. A pharmaceutical composition containing 17 alpha-dihydroequilin, a C.sub.2 -C.sub.6 alkanoyloxy ester thereof or a pharmaceutically acceptable salt of it's sulfate or phosphate ester, in the absence of naturally occurring estrogenic sreroids, and a pharmaceutically acceptable carrier therefor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.